News & Events about Oncternal Therapeutics Inc.
Globe Newswire
2 months ago
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented in an ...
Globe Newswire
4 months ago
SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (...
Globe Newswire
4 months ago
SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Conference on ...
Thinking about buying stock in Redbox, New Oriental Education, Day One Biopharmaceuticals, Exicure, or Oncternal Therapeutics? Thinking about buying stock in Redbox, New Oriental Education, Day One Biopharmaceuticals, Exicure, or Oncternal Therapeutics? PR Newswire NEW YORK, June 13, 2022 NEW YORK...
Globe Newswire
7 months ago
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus ibrutinib ...